Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation
Stress Test And Cash Crunch Continues
Executive Summary
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
You may also be interested in...
Understanding How To Develop BTK Inhibitors In MS Is Evolving
Having a reversible BTK inhibitor in the multiple sclerosis armamentarium could be the best way to favorably impact the treatment landscape.
Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears
Adding to a growing pattern within the BTK inhibitor pipeline for multiple sclerosis, the US FDA has placed Merck’s evobrutinib on a partial clinical hold following two liver injury incidents, prompting questions over its ultimate approvability.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.